Cumberland Pharmaceuticals (CPIX) Reports Q3 EPS of $0.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cumberland Pharmaceuticals Reports Third Quarter & Year To Date 2016 Financial Results
November 1, 2016 4:05 PM EDTNASHVILLE, Tenn., Nov. 1, 2016 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2016 financial results with Net Revenues of $8.8 million and Adjusted Earnings of $1.0 million or $0.06 per share. Earnings prior to adjustments were $0.1 million or $0.01 per share.
As of September 30, 2016, the Company had approximately $91 million in Total Assets including $50 million in cash and marketable securities. Total Liabilities were approximately $17 million and Total Shareholder's Equity was just under $75... More
